Target intelligence / Profile preview

Pro-oxidant copper binding sites

Molecular classification
Metal-binding site, Protein-metal complex, Other
01

Overview

Pro-oxidant copper binding sites are specific structural motifs found on proteins such as amyloid-beta (Aβ), alpha-synuclein, and the prion protein, which coordinate copper ions (Cu+/Cu2+) to form redox-active complexes (Bush, 2003, PMID: 12757816). These sites facilitate metal-catalyzed oxidation (MCO), a process where the bound copper undergoes redox cycling in the presence of biological reductants like ascorbate, leading to the catalytic production of reactive oxygen species (ROS) such as hydrogen peroxide and hydroxyl radicals (Barnham & Bush, 2014, PMID: 24737124). The resulting oxidative stress is a primary driver of neuronal damage, lipid peroxidation, and protein aggregation in neurodegenerative conditions like Alzheimer's and Parkinson's diseases (Fallon et al., 2021, PMID: 33414134). Therapeutic intervention targets these sites using metal-protein attenuating compounds (MPACs) or metal ionophores, which aim to disrupt the pathological metal-protein interaction or stabilize the metal in a non-redox-active state. Unlike traditional chelators, these agents are designed to selectively target the labile metal pool associated with protein aggregates, thereby reducing oxidative damage and restoring metal homeostasis without causing systemic metal deficiency.

Other names
Redox-active copper binding sitesMetal-catalyzed oxidation sitesCopper-protein coordination sitesAβ-copper binding sitesMCO sites
02

Mechanism of action

Metal-protein attenuation and redox silencing through competitive coordination or ionophore-mediated redistribution of copper ions from pathological protein complexes.

03

Biological functions

Redox catalysisMetal ion coordinationReactive oxygen species generationOther
04

Disease associations

Neurodegenerative diseaseAlzheimer's diseaseParkinson's diseaseAmyotrophic lateral sclerosisOther
05

Safety considerations

Systemic depletion of essential metalsOff-target inhibition of essential metalloenzymesPotential for neurotoxicity via metal redistribution to unintended compartments
06

Interacting drugs

PBT2

4 more in the full profile.

07

Biomarkers

Protein carbonyls8-hydroxy-2'-deoxyguanosine (8-OHdG)Cerebrospinal fluid copper levelsF2-isoprostanes

Beyond the preview

Go deeper on Pro-oxidant copper binding sites.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pro-oxidant copper binding sites.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call